Antibiotic Use In First Four Years Of Childhood Not Associated With T1D, Celiac Disease

“Within the first four years of life, exposure to commonly prescribed antibiotics for children – cephalosporins, penicillins, and macrolides – was not associated with autoimmunity development for celiac disease and type 1 diabetes [T1D],” researchers found. The findings of the 8,495-child study were published online in https://www.medpagetoday.com/endocrinology/type1diabetes/68413

Women Who Consume Foods With A Higher Dietary Acid Load May Be More Likely To Develop Gestational Diabetes,

reports, “Women who consume foods with a higher dietary acid load are more likely to develop gestational diabetes when compared with women who consume a lower dietary acid load,” researchers concluded after analyzing “data from 263 healthy pregnant women and 200 pregnant women with gestational diabetes between five and 28 weeks’ gestation,” then adjusting for confounding factors. The findings were published online in Clinical Nutrition. https://www.healio.com/endocrinology/diabetes/news/in-the-journals/%7Bb7093e19-8ca2-4b7e-a745-cdc961f54554%7D/higher-dietary-acid-load-increases-gestational-diabetes-risk?nc=1

Vitamin D And Calcium From Food, But Not Supplements, May Be Linked To Reduced Risk For Early Menopause,

reported that research suggests “vitamin D and calcium from food, but not supplements, were associated with a decreased risk for early menopause, and the hormones in dairy food may partly explain why.” Investigators found that “compared with women with the least amount of vitamin D in their diet, those with the most were 17% less likely to undergo menopause before the age of 45.” But, “compared with women who did not take vitamin D supplements, those who took the recommended daily allowance of 600 IUs or more had no significant change in risk.” The findings were published online in the American Journal of Clinical Nutrition. https://www.medpagetoday.com/clinicalfocus/osteoporosis/68303

Does Fat Intake Play a Role in Pediatric MS Relapse? Observational study offers some evidence of association, not causality

https://www.medpagetoday.com/Neurology/MultipleSclerosis/68437?xid=NL_breakingnews_2017-10-10&eun=g721819d0r

Fungal Superbug' Raising Fears But few Candida auris cases so far in U.S.

Even when the fungus, Candida auris, is not completely resistant to the available antifungal drugs, it can be a challenge, Chiller told a symposium here at the annual IDWeek meeting, sponsored jointly by the Infectious Diseases Society of American (IDSA), the Pediatric Infectious Diseases Society (PIDS), the Society for Healthcare Epidemiology of America (SHEA), and the HIV Medicine Association (HIVMA). The fungus, first reported in 2009 and since seen around the world, is readily transmitted since it colonizes both the skin and the environment, but is not easily identified or treated. And like other Candida species, it can cause severe invasive disease and death. Candidemia is already the most common bloodstream infection in the U.S., Chiller said, with a 30% mortality rate. But it has usually been thought of as an "autoinfection https://www.medpagetoday.com/MeetingCoverage/IDWeek/68343?xid=nl_mpt_DHE_2017-10-06&eun=g721819d0r&pos=1

Kids' Experiment Shows Value of Washing Hands Side benefit: less absenteeism from school

https://www.medpagetoday.com/MeetingCoverage/IDWeek/68353?xid=nl_mpt_DHE_2017-10-06&eun=g721819d0r&pos=0

Antibiotic Pipeline Overflows New drugs and new classes intrigue IDWeek audience

"We have new drugs for bad bugs," quipped co-moderator Cesar Arias, MD, PhD, of the University of Texas Medical School at Houston. The new drugs include beta-lactamase inhibitors, a cephalosporin, an aminoglycoside, a fluoroquinolone, and a tetracycline, as well as several first-in-class medications. Themes that emerged during the discussion were twofold: The new drugs in established classes aim to overcome some of the safety issues of their predecessors And the approach to resistance is much more nuanced than it has been in the past, so that doctors will soon be able to choose medications that target specific mechanisms of resistance Already available is delafloxacin (Baxdela), a new fluoroquinolone that won FDA approval in June for acute bacterial skin and skin structure infections (ABSSSI), according to Sue Cammarata https://www.medpagetoday.com/MeetingCoverage/IDWeek/68389?xid=nl_mpt_DHE_2017-10-07&eun=g721819d0r&pos=0